Insights from Patients and Physicians About Use of Evolocumab for LDL-C Management
A large majority of patients and physicians reported high satisfaction levels about their experience with evolocumab treatment. This may help inform treatment decisions when choosing lipid-lowering therapy in patients with ASCVD and elevated LDL-C concentrations.
Authors
- Bethany Kalich (ORCID: https://orcid.org/0000-0002-1220-3484)
- Laney K. Jones (ORCID: https://orcid.org/0000-0002-6182-5634)
- Eduard Sidelnikov (ORCID: https://orcid.org/0000-0001-9384-2255)
- Amalia DeBrosse
- Peter Okorozo
Institutions
- Department of Health and Social Care (GB)
- Amgen (United States) (US)
- Amgen (Switzerland) (CH)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1007/s12325-025-03322-4
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen